1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nexalin Technology received a Nasdaq Hearings Panel decision allowing its common stock to stay listed on The Nasdaq Capital Market, subject to conditions. The company must meet the $1.00 minimum bid price by September 28, 2026 and the $2,500,000 stockholders' equity requirement by January 4, 2027, or its stock faces delisting.
Panel granted continued listing in a notice received September 25, 2026.
Company must show a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions.
Stockholders' equity must meet the $2,500,000 minimum by January 4, 2027.
Filing states there can be no assurance the company will meet the conditions.
Unicycive Therapeutics disclosed that a securities class action was filed on September 3, 2026, in the U.S. District Court for the Northern District of California against the company and certain officers. The suit alleges violations of federal securities laws tied to public statements about the company's new drug application for oxylanthanum carbonate phosphate binder. The company says the claims are meritless and plans to defend the lawsuit vigorously, but the filing does not state any financial impact.
Class action filed September 3, 2026, in U.S. District Court for the Northern District of California
Suit names the company and certain officers and alleges federal securities law violations
Allegations relate to public statements about the new drug application for oxylanthanum carbonate phosphate binder for hyperphosphatemia in dialysis patients with chronic kidney disease
Company says the claims are meritless and intends to vigorously defend
Gossamer Bio received a Nasdaq letter on September 25, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had completed a 1-for-80 reverse stock split on September 10, 2026, with split-adjusted trading beginning September 11, 2026. The filing shows the listing issue is resolved, but it does not report any change to financial results.
Nasdaq letter dated September 25, 2026 confirms compliance with the minimum bid price rule under Nasdaq Listing Rule 5450(a)(1)
The matter followed a Nasdaq letter received April 8, 2026, after the stock failed to trade at $1.00 or more for 30 consecutive business days
1-for-80 reverse stock split effective September 10, 2026; split-adjusted trading began September 11, 2026
CapsoVision said the U.S. Food and Drug Administration cleared AI Highlights, an AI-assisted reading feature for its CapsoCam Plus capsule endoscopy system, on September 25, 2026. The company announced the clearance on September 28, 2026, and the filing contains no revenue, profit, or guidance figures, so its direct financial effect on shareholders is not quantified.
FDA clearance received September 25, 2026; announced September 28, 2026
Tool flags suspected abnormal lesions in small bowel capsule studies to reduce physician review time
Intended for adult and pediatric patients over two years old with suspected small bowel bleeding; does not replace gastroenterologists' diagnosis
A federal jury awarded Ramaco Resources' subsidiary $30.0 million in damages on September 25, 2026, in its lawsuit against Federal Insurance Company and ACE American Insurance Company over a denied claim for a 2018 silo failure at the Elk Creek plant. The court entered judgment on the verdict, but attorneys' fees remain to be decided and the defendants may still challenge the award through post-trial motions or an appeal.
Jury awarded $27.5 million for net economic loss and $2.5 million for aggravation and inconvenience.
Judgment was entered on September 25, 2026, against Federal Insurance Company and ACE American Insurance Company.
Attorneys' fees were not decided by the jury and will be determined by the Court.
Defendants may file post-trial motions within 28 days of judgment and a notice of appeal within 30 days of the final judgment.
After the market close on September 25, 2026, a jury awarded $5.7 billion in damages to the plaintiff in Taction Technology, Inc. v. Apple Inc., a case in which Burford has a financial entitlement. Burford says that if the verdict were paid as is, its entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds, but the amount is likely to change in post-trial and appellate proceedings. For shareholders, the verdict is not a final judgment or cash received, and Burford warns it could recover substantially less or incur a total loss.
Jury verdict of $5.7 billion in damages, announced in a release dated September 28, 2026, after the market close on Friday, September 25, 2026
If paid as is, Burford's entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds
Apple has filed a motion for judgment as a matter of law, and the Federal Circuit will scrutinize large verdicts on appeal
Burford states that it could recover substantially less than the verdict amount or, in certain circumstances, incur a total loss
GEE Group's audit committee is conducting an independent inquiry into an Executive Employment Agreement dated April 27, 2023 with Allison Dewan, the daughter of Chairman and CEO Derek Dewan, who is named Vice President of Corporate Development. The agreement and its terms had not previously been disclosed in SEC filings, and the committee is reviewing its origin, authorization, related disclosure controls, and whether it should have been disclosed as a related party transaction.
Agreement dated April 27, 2023 names Allison Dewan Vice President of Corporate Development
Initial base salary of $110,000 per year, with a five-year term ending April 26, 2028
Audit committee is reviewing whether the agreement should have been disclosed as a related party transaction, given compensation above $120,000
Filing signed by CFO Kim Thorpe on September 28, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.